For patient-related information about the ICT-107 cancer vaccine phase II program please:

  1. Access the ICT-107 FAQ (Frequently Asked Questions) click here.
  2. Send an email message to clintrials@imuc.com, including your contact information and your specific questions.
  3. Call 818 264 2315 and leave a brief message, including your contact information and questions.

Someone knowledgeable about the ICT-107 clinical program will respond to your inquiry shortly.

PRESS RELEASES

Thursday, March 13, 2014
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results read more ...
Tuesday, March 11, 2014
ImmunoCellular Therapeutics Announces Change to Meeting Date for Annual Meeting of Stockholders read more ...
Tuesday, March 04, 2014
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on read more ...
Monday, March 03, 2014
ImmunoCellular Therapeutics to Present at ROTH Conference on March 11th read more ...
Tuesday, February 25, 2014
ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European read more ...

EVENTS

Thursday, March 13, 2014
Immunocellular Therapeutics 4QYE 2013 Financial Results Conference Call and Webcast
Tuesday, March 11, 2014
Webcast: ImmunoCellular Therapeutics presentation at 26th Annual 2014 ROTH Conference
 
Copyright 2014 by Immunocellular Therapeutics, Ltd.
All Rights Reserved